An Early Phase 1 interventional study of Safety of intracameral levofloxacin in cataract surgery and Use of intracameral cefazolin in cataract surgery in Cataract, sponsored by Tan Tock Seng Hospital. Completed at 2 sites in Singapore. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-02.
Sponsored by Tan Tock Seng Hospital · Early Phase 1, Interventional, and Supportive care
Patients with senile cataracts undergoing phacoemulsification were assigned to receive intracameral levofloxacin (0.1ml/0.5mg) or intracameral cefazolin (0.1ml/1mg). The primary endpoint was the occurrence of endophthalmitis during the 3 month follow-up period. Secondary endpoints included best-corrected visual acuity (BVCA), the presence of anterior chamber (AC) inflammation with grading of AC cells and presence of flare, along with intraocular pressure (IOP), corneal cell thickness (CCT), central foveal thickness (CFT) and cell density.
1,726 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's enrollment of 50 is below the median of 80 across 1,171 interventional studies indexed under Cataract.
Browse Cataract studies →Tan Tock Seng Hospital is the lead sponsor of 108 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Eligible and recruited patients are randomized to intracameral levofloxacin or intracameral cefazolin during cataract surgery
Drug: Safety of intracameral levofloxacin in cataract surgery · Drug: Use of intracameral cefazolin in cataract surgery
Eligible and recruited patients were randomized to intracameral levofloxacin or intracameral cefazolin during cataract surgery
Drug: Safety of intracameral levofloxacin in cataract surgery · Drug: Use of intracameral cefazolin in cataract surgery
Intracameral levofloxacin (0.1ml/0.5mg)
Intracameral cefazolin (0.1ml/1mg)
Number of Participants with Treatment related adverse events to Intracameral Cefazolin versus Levofloxacin
Time frame: From cataract surgery through to study completion, an average of 1 year
Plan to share: No — Upon publication, we will be providing contact details such that keen parties can approach us to get clarification or access to the data.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.